Diligent Pharma Named to 2025 Inc. 5000 List of Fastest-Growing Private Companies in America

We are proud to announce that Diligent Pharma has been named to rank #1,378 on the 2025 Inc. 5000 list of the fastest-growing privately held companies in America. This recognition affirms our commitment to accelerating clinical trial execution so that life-saving treatments can reach patients faster.

Published each year by Inc. magazine, the list honors private companies that have demonstrated exceptional revenue growth. Diligent Pharma is proud to be counted among this year's honorees.

This achievement is more than a marker of business success. It reflects the trust our clients have placed in us to help them navigate the complexities of clinical research.

Representatives from our team attended the Inc. 5000 Conference & Gala, where sessions reinforced themes that resonate deeply with how we operate: leading with purpose, working in service of others, and maintaining a relentless pursuit of providing value to clients. These principles are woven into everything we do at Diligent Pharma.

This recognition belongs to many. It belongs to our clients, whose commitment to advancing clinical research challenges us to keep raising the bar. It belongs to our partners, who work alongside us to drive innovation in trial execution. And it belongs to the Diligent Pharma team, whose dedication to quality and efficiency makes this work possible. We are humbled by their contributions.

Diligent Pharma's growth reflects a broader truth: clinical research is more demanding than ever. Sponsors and vendors alike face pressure to move faster, maintain rigorous standards, and adopt new technologies—all while keeping patients at the center. The organizations succeeding in this environment are those committed to enabling innovation and setting the highest standards for quality and efficiency.

The Inc. 5000 honor gives us an opportunity to reflect on the work ahead. We remain committed to enabling the adoption of innovation in clinical trial execution and ensuring that the highest standards guide everything we do.

To our clients, our partners, and our team: thank you for your trust, your collaboration, and your shared belief that clinical research can be better. We are grateful for the opportunity to drive progress in support of patients, and we look forward to what we will accomplish together.